Fund moves
3.4%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
OBX · NASDAQ · Pharmaceutical Preparations · No 10-K yet
$12.21+0.14 (+1.16%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
Obsidian Therapeutics (OBX) · oqro.io/stocks/OBX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
−64.1% (−$21.79) from Aug 4, 2026 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $34.00 on Aug 4, 2026 to $12.21 on Nov 18, 2026 (−64.1%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Cambridge, MA. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
$754M
Short interest: 1.18M shares sold short (1.9% of shares outstanding), +9.6% vs the previous count, 3.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Against the S&P 500 over the year
Since Aug 4, 2026, OBX is down 64.1% and the index fund is down 5.3%: 59 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much OBX moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
On the public record for Obsidian Therapeutics over the 12 months to Nov 19, 2026: 1 clinical trial.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Deals
Things to keep in mind
Revenue
$0
Year earlier: $0
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $66.5M, at Sep 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Changed auditor
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in tumor skin. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
From a 13F filed Nov 6, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No open-market purchase by an insider of Obsidian Therapeutics is on record in SEC filings since 2006.
No open-market sale by an insider of Obsidian Therapeutics (OBX) was filed with the SEC in the last 90 days.
No trade in Obsidian Therapeutics (OBX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
4 certified in FY2026 Q3, vs 2 a year earlier. 4 positions in total, median offered wage $121K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Fails to deliver: 158K shares (about $1.93M) were not delivered on time for settlement on Oct 15, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.